Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, hematologic disease characterized by complement-mediated hemolysis, thrombosis, and various degrees of bone marrow dysfunction. Until recently, C5 inhibition with eculizumab or ravulizumab represented the only therapies approved for pati...

Descripción completa

Detalles Bibliográficos
Autor principal: Wong, Raymond S.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340389/
https://www.ncbi.nlm.nih.gov/pubmed/35923770
http://dx.doi.org/10.1177/20406207221114673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340389/
https://www.ncbi.nlm.nih.gov/pubmed/35923770
http://dx.doi.org/10.1177/20406207221114673

Ejemplares similares